Tvardi Therapeutics, Inc. (TVRD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.91+3.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TVRD
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Develop next-generation STAT3 inhibitor TTI-109 for ulcerative colitis and additional inflammatory and proliferative diseases, pending IND clearance and funding.
Stated as a priority in 3 disclosures including 2026-Q1 and 2026-Q2. Management reported TTI-109 Phase 1 results confirming prodrug design, improved tolerability, and pharmacodynamic target engagement. The company plans to initiate a clinical trial in ulcerative colitis in 2027, pending IND clearance and additional funding. This priority is actively progressing with clinical data and development plans, consistent with management's statements.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13363).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Plans to initiate clinical trial of TTI-109 in UC in 2027, subject to IND clearance and funding.”
“TTI-109 Phase 1 healthy volunteer topline data and clinical development strategy anticipated in June 2026.”
Complete and announce topline data from ongoing Phase 1b/2 REVERT LIVER CANCER trial of TTI-101 in hepatocellular carcinoma in second half of 2026.
Stated as a priority in 2 of last 2 quarters (2026-Q1 and 2026-Q2). Management confirmed the Phase 1b/2 REVERT LIVER CANCER trial of TTI-101 is on track for topline data in second half of 2026. This aligns with the clinical development timeline and remains on track as planned.
“TTI-101 Phase 1b/2 HCC topline data expected in 4Q 2026.”
“Phase 1b/2 trial remains on track to report topline results in 2H 2026.”
Manage cash and funding to sustain operations through clinical readouts, including HCC topline data in 3Q 2027 and other milestones.
Stated as a priority in 3 of last 3 quarters. Management has consistently communicated that cash runway is sufficient to fund operations through clinical readouts, extending from Q4 2026 to the HCC topline readout into 3Q 2027. Cash and equivalents declined from $30.8M at 2025-Q4 to $15.8M at 2026-Q2, reflecting ongoing operating losses. The trajectory shows ongoing cash burn but management maintains runway guidance consistent with stated plans.
“Cash sufficient to fund operations through HCC topline readout into 3Q 2027.”
“Cash runway sufficient to fund operations through clinical readouts and into Q4 2026.”
“Cash runway sufficient to fund operations through clinical readouts and into Q4 2026.”
Ensure sufficient cash to fund operations through clinical readouts and into the fourth quarter of 2026.
Develop TTI-109, a next-generation STAT3 inhibitor, into Phase 2 trials and expand into dermatologic, gastrointestinal, and ulcerative colitis indications.
Over the trailing year it converted -1.83x of net income into operating cash flow. Historically, Health Care names rated fragile grew net income 32% of the time over the next year (vs 54% for the rest of the cohort, n=2490).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity (low R² over the window).
13 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.